Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cybin Inc. before investing.

In this article, we go over a few key elements for understanding Cybin Inc.’s stock price such as:

• Cybin Inc.’s current stock price and volume
• Why Cybin Inc.’s stock price changed recently
• Upgrades and downgrades for HELP from analysts
• HELP’s stock price momentum as measured by its relative strength

About Cybin Inc. (HELP)

Before we jump into Cybin Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Want to learn more about Cybin Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cybin Inc..

Cybin Inc.’s Stock Price as of Market Close

As of April 27, 2026, 10:32 AM, CST, Cybin Inc.’s stock price was $5.975.

Cybin Inc. is up 6.51% from its previous closing price of $5.610.

During the last market session, Cybin Inc.’s stock traded between $5.620 and $6.260. Currently, there are approximately 42.52 million shares outstanding for Cybin Inc..

Cybin Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cybin Inc. Stock Price History

Cybin Inc.’s (HELP) price is currently up 24.48% so far this month.

During the month of April, Cybin Inc.’s stock price has reached a high of $6.260 and a low of $4.800.

Over the last year, Cybin Inc. has hit prices as high as $9.830 and as low as $4.290.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cybin Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there were 0 analysts who downgraded Cybin Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cybin Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cybin Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cybin Inc. (HELP) by visiting AAII Stock Evaluator.

Relative Price Strength of Cybin Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Cybin Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Cybin Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cybin Inc. Stock Price: Bottom Line

As of April 27, 2026, Cybin Inc.’s stock price is $5.975, which is up 6.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cybin Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.